methylphenidate

FDA Drug Profile — Methylphenidate Transdermal System, Methylphenidate, Daytrana

methylphenidate is listed in the FDA National Drug Code directory with 16 NDC codes, marketed under brand names including Methylphenidate Transdermal System, Methylphenidate, Daytrana. Available dosage forms: patch, capsule, extended release.

Drug details

Generic Name
methylphenidate
Brand Names
Methylphenidate Transdermal System, Methylphenidate, Daytrana
Application Number
NDA021514
Sponsor
PADAGIS US LLC
NDC Codes
16
Dosage Forms
PATCH, CAPSULE, EXTENDED RELEASE
Routes
TRANSDERMAL, ORAL
Active Ingredients
METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Methylphenidate transdermal system is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Us e The use of methylphenidate transdermal system is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.8) , Use in Specific Populations (8.4) ] . Methylphenidate transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. ( 1 ) Limitations of Use The use of methylphenidate transdermal system is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.8 , 8.4 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.